Table 1.
Patients' clinical data.
| Clinical characteristics | ctl (n=31) | DCM (n=41) | ICM (n=31) | |
|---|---|---|---|---|
| Ages (years) | ||||
| Mean | 50.29 ± 7.62 | 49.31± 8.99 | 55.26± 7.47 | |
| Range | 38±65 | 29±62 | 29±66 | |
| Median | 49 | 50 | 49 | |
| Sex | ||||
| Men | 14(45.2%) | 27(65.9%) | 21(67.7%) | |
| Women | 17 | 14(34.1%) | 10(32.3%) | |
| Active smoker | 7(22.5%) | 14(34.1%) | 16(51.6%) | |
| History of drinking | 4(12.9%) | 13(31.7%) | 4(12.9%) | |
| BUN,mmol/L | 4.96± 0.17 | 7.31± 0.45 | 7.35± 0.63 | |
| Creatinine,umol/L | 64.75 ±2.49 | 86.90±7.54 | 98.86±15.99 | |
| UA,umol/L | 299.12±18.52 | 455.65±22.87∗ | 373.95±24.68∗ | |
| ALT,u/L | 22.27±2.25 | 40.09±6.35∗ | 81.78±44.95 | |
| AST,u/L | 21.06±1.70 | 35.13±3.21 | 121.68±67.65∗† | |
| NYHA class | ||||
| III | 21(51.2%) | 16(51.61%) | ||
| IV | 20(48.8%) | 15(48.4%) | ||
| Diagnosis-related factors | ||||
| hsCRP,mg/L | 2.50±0.53 | 6.08±1.09∗ | 43.7±10.77∗† | |
| NT-pro-BNP,pg/ml | 60.43±6.91 | 3649.45±909.85∗ | 7603.3±3482.96∗ | |
| LVEF,% | 64.40±0.99 | 30.45±1.13∗ | 33.39±1.19∗ | |
| LVEDD,mm | 47.28±0.68 | 69.03±1.11∗ | 64.48±1.12∗ | |
| Concurrent medication,% | ||||
| Nitroprusside sodium | 65.8 | 83.9 | ||
| Beta-blockers | 21.9 | 77.4 | ||
| ACEI/ARB | 60.9 | 87 | ||
| Diuretics | 82.9 | 96.7 | ||
| Digitoxin | 63.4 | 67.7 | ||
| Aspirin | 43.9 | 51.5 |
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; NYHA class, New York Heart Association class; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; hsCRP, high-sensitivity C-reactive protein. Data are expressed as mean±SEM or number(%); ∗P < 0.05 compared with control group; †P<0.05 compared with DCM group.